Gonadorelin
GnRH / LHRH / Factrel / Lutrepulse
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous hypothalamic decapeptide that controls reproductive hormone secretion. When administered in pulsatile fashion, it stimulates the anterior pituitary to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for diagnostic testing of pituitary function and therapeutically to maintain fertility during testosterone replacement therapy.
Mécanisme d'action
Synthetic analog of endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates FSH and LH release from the anterior pituitary. Continuous administration paradoxically downregulates the HPG axis through receptor desensitization.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Pulsatile protocols use 25-100mcg subcutaneously every 90-120 minutes via pump to mimic natural GnRH pulses. Diagnostic test protocols use a single 100mcg IV dose. Continuous dosing protocols (suppressive) not commonly used with the native peptide.
Notes de recherche
Clinical Research Status
Gonadorelin has FDA approval as a diagnostic agent (Factrel) for evaluating pituitary gonadotroph function and in pulsatile form (Lutrepulse) for hypothalamic amenorrhea, though the latter formulation has been discontinued. It is increasingly prescribed off-label by TRT clinics as an alternative to HCG for maintaining LH/FSH secretion and testicular function. Current research focuses on its role in preserving spermatogenesis during exogenous testosterone administration.
Key Published Findings
Pulsatile GnRH administration has been demonstrated to restore ovulation in women with hypothalamic amenorrhea with pregnancy rates of 20-30% per cycle. In male patients on TRT, subcutaneous gonadorelin at doses of 100-400 mcg administered two to three times daily can maintain measurable LH and FSH levels. The pulsatile pattern is critical as continuous administration paradoxically suppresses gonadotropin release through receptor downregulation.
Safety Profile
Gonadorelin has an excellent safety profile with minimal systemic side effects when used at appropriate doses. Injection site reactions are the most commonly reported adverse event. Headache, flushing, and abdominal discomfort occur rarely. The main clinical concern is ensuring pulsatile rather than continuous dosing patterns to avoid the paradoxical suppressive effect seen with GnRH agonists.
Comparison to Related Compounds
Unlike HCG which directly stimulates Leydig cells, gonadorelin works upstream by stimulating the pituitary to release endogenous LH and FSH, maintaining more physiological hormonal signaling. Compared to GnRH agonists like leuprolide or triptorelin, gonadorelin at pulsatile doses stimulates rather than suppresses the reproductive axis. It offers a more physiological approach to fertility preservation during TRT but requires more frequent dosing than HCG.
Community Observations
Gonadorelin gained significant popularity after 2020 when compounded HCG became harder to obtain, with many TRT clinics switching patients to gonadorelin protocols. Practitioners note that effective use requires proper dosing frequency (typically twice daily subcutaneous injections) to mimic natural GnRH pulsatility. Some clinicians report that gonadorelin is less reliably effective than HCG for testicular size maintenance, though individual responses vary.
Moitié de vie
~2-4 minutes
Réconstitution
Bacteriostatic water (BAC)
Conservation
Lyophilisé
Refrigerate 2-8C up to 12 months.
Réconstitué
Refrigerate 2-8C. Use within 14 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que Gonadorelin ?
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous hypothalamic decapeptide that controls reproductive hormone secretion. When administered in pulsatile fashion, it stimulates the anterior pituitary to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for diagnostic testing of pituitary function and therapeutically to maintain fertility during testosterone replacement therapy.
Comment agit Gonadorelin ?
Synthetic analog of endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates FSH and LH release from the anterior pituitary. Continuous administration paradoxically downregulates the HPG axis through receptor desensitization.
Quel est le statut réglementaire de Gonadorelin aux États-Unis ?
FDA-approved for diagnostic use (Rx only)
Quelle est la demi-vie de Gonadorelin ?
~2-4 minutes
Sous quels autres noms Gonadorelin est-il connu ?
GnRH, LHRH, Factrel, Lutrepulse
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète